Status:
RECRUITING
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
Lead Sponsor:
Peking University First Hospital
Conditions:
Inflamatory Bowel Disease
Eligibility:
All Genders
18+ years
Brief Summary
Inflammatory bowel disease (IBD) is a group of chronic progressive gastrointestinal diseases that can recur throughout life and for which there is no cure. Biologics, the first line of treatment, are ...
Eligibility Criteria
Inclusion
- Patients who are clinically diagnosed with IBD in our hospital
- Disease activity is in the active stage
- Receiving biologics after diagnosis
- Have relevant data on clinical evaluation results after receiving biologics treatment
Exclusion
- IBD patients who have not been treated with biologics after diagnosis
- Patients diagnosed with IBD but also with other autoimmune diseases that require biologics to be treated
- Patients with hematological diseases and other systemic chronic inflammatory diseases involving the intestine Patients with serious complications including malignant tumors and gastrointestinal perforation.
Key Trial Info
Start Date :
August 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07181525
Start Date
August 15 2025
End Date
December 31 2026
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, China